Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2024 Earnings Conference Call August 12, 2024 4:30 AM ET
Company Participants
John Menditto - VP, IR & Corporate Communications
David Mazzo - President & CEO
James Nisco - Chief Accounting Officer
Kristen Buck - EVP, Research and Development & Chief Medical Officer
Conference Call Participants
Steve Brozak - WBB securities
Sara Nik - H.C. Wainwright
Will Hidell - Brookline Capital Markets
Pete Enderlin - MAZ Partners
Robert Sassoon - Water Tower Research
Operator
Welcome to the Lisata Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. Following managements prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, Monday, August 12, 2024.
I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Lisata. Please go ahead, sir.
John Menditto
Thank you, operator, and good afternoon, everyone. Welcome to Lisata's second quarter 2024 conference call to discuss our financial results and to provide a business update. Joining me from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer.
Shortly before this call, we issued a press release announcing our second quarter 2024 financial results, which is available under the Investors and News section of the company website along with a webcast replay of this call. If you have not received this news release or if you'd like to be added to the company's e-mail distribution list, please subscribe to e-mail alerts on the company website or e-mail me at jmenditto@lisata.com to be added.
Before we begin, I will remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lisata. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its Forms 10-Q, 8-K and 10-K which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Monday, August 12, 2024. Lisata Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.